Heart Attack Research Program: Platelet Sub-Study (HARP)
ConditionMyocardial Infarction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age21-99
SponsorNYU Langone Health
About this trial
This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.
Eligibility criteria
Qualifiers
Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
Elevation of troponin to above the laboratory upper limit of normal (ULN)
ST segment elevation of ≥1mm on 2 contiguous ECG leads
Willing to provide informed consent and comply with all aspects of the protocol
Disqualifiers
Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
Pregnancy
Thrombolytic therapy for STEMI (qualifying event)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
350 Participants
are grouped into 3 trial groupsLocations
1NYU Langone Medical Center10016, New YorkNew York, United States
Sponsors and collaborators
NYU Langone Health
Lead sponsor
Source ClinicalTrials.gov